Yixi Dynamics | Yixi Biotech's Fucosyllactose Receives National Medical Products Administration Filing for New Cosmetic Ingredient
Yixi Biotech's fucosyllactose has received cosmetic new ingredient registration from the National Medical Products Administration.
Yixi's Fucosyllactose Clears Cosmetic New Ingredient Filing with China's National Medical Products Administration
On June 27, 2024, the National Medical Products Administration (NMPA) released cosmetic new ingredient filing No. 20240046. The filing was submitted by Suzhou Yixi Biotechnology Co., Ltd. for the ingredient fucosyllactose.
Source: National Medical Products Administration official website
A Star Ingredient Crosses Over
In March 2024, Yixi Biotech's 2'-FL officially received approval from the National Health Commission, clearing the path for the product's compliance in the food sector.
In cosmetics, fucosyllactose is already listed in the EU's CosIng database and the US PCPC ingredient directory, with the INCI name FUCOSYLLACTOSE (CAS: 41263-94-9), where it primarily functions as a skin conditioning agent and skin protectant. This NMPA cosmetic new ingredient filing further broadens the application scenarios for HMOs, and we expect HMOs to bring fresh energy to the cosmetics market going forward.
Research has demonstrated that fucosyllactose offers melanin reduction, antioxidant, skin protection, moisturizing, and dermatitis improvement benefits. It can be widely applied in cosmetics to develop safe, stable products with whitening, antioxidant, and repair functions — including cleansing products (facial cleansers, shampoos, body washes, etc.) and skincare products (toners, moisturizing lotions, etc.).
For product inquiries, please contact info@yixilife.com.
About Yixi Biotech
Yixi Biotech is a synthetic biology ingredient company focused on human and animal nutrition and health, dedicated to using technology and creativity to expand the boundaries of human food sources.
The company's lead pipeline, human milk oligosaccharides (HMOs), has achieved industrial-scale production with complete independent intellectual property rights from strain construction to process development, making it a leading player in China's HMOs sector. Its second product pipeline, feed protein, is also approaching the industrialization stage.
To date, the company has nearly 100 employees and has completed three rounds of financing. Its Series A funding round is currently underway.
— THE END —
